ChartMill is a comprehensive online stock research platform designed to empower traders and investors with advanced tools for technical and fundamental analysis. The company provides a robust stock screener that allows users to filter thousands of stocks across major exchanges like NYSE, NASDAQ, and EURONEXT, using over 180 customizable technical and fundamental parameters to identify trading opportunities.
Tetra Tech (TTEK) reports record FY2025 results, beating EPS estimates. The environmental consulting firm also provides strong FY2026 guidance and announces a dividend increase.
Digi International (DGII) beat Q4 earnings and revenue estimates, sparking a 13% stock surge. The IoT firm also reported strong recurring revenue growth and issued optimistic future guidance.
BioCardia reports Q3 2025 results with no revenue and a wider-than-expected loss. The clinical-stage biotech continues advancing its cell therapy pipeline for heart failure.
Paysign Q3 2025 earnings crush estimates with 41.6% revenue growth. Its high-margin pharma business soared 141.9%, driving strong profitability and a raised 2025 outlook.
Southland Holdings reported a Q3 2025 loss due to a one-time tax charge, but showed strong operational progress with improved gross profit and a $2.26B backlog.
Tecogen's Q3 2025 results show revenue beat estimates, but losses widened. The clean energy firm highlights strong progress in its strategic data center cooling initiatives.
374Water (SCWO) reported Q3 2025 revenue growth but missed analyst estimates, with a widening net loss. The stock fell as future guidance trails market expectations.
Fidelis Insurance (FIHL) Q3 2025 earnings beat EPS estimates, but revenue fell short. The company showed strong underwriting with a 79.0% combined ratio.
CXAPP (CXAI) reported mixed Q3 2025 results, with a 42% earnings beat but a 16% revenue miss. The company highlighted strong margins and a 10% rise in recurring revenue.
Talphera secured $17M in strategic financing to fund operations through its Niyad PMA in late 2026, despite a negative market reaction to its Q3 earnings.
Ardent Health posted a strong Q3 earnings beat but slashed its full-year 2025 guidance, causing the stock to plummet over 25% as investors focused on future headwinds.
Serve Robotics posts mixed Q3 2025 results, missing revenue and EPS estimates. Despite a 66% delivery growth and a new DoorDash partnership, the stock fell.
Intellinetics (INLX) reported mixed Q3 2025 results, beating earnings estimates but missing on revenue. Despite the revenue miss, the stock surged 28.7% on strong SaaS growth and a positive outlook.
GRAIL (GRAL) Q3 2025 earnings beat estimates on revenue and EPS, sending the stock higher. Strong growth for its Galleri cancer test drove the positive results.
Oruka Therapeutics reports Q3 2025 results, beating EPS estimates. With a strong $500.9M cash position, the biotech advances its clinical pipeline for ORKA-001 and ORKA-002.
Firefly Aerospace (FLY) Q3 earnings beat revenue and EPS estimates, driving a 14.6% stock surge. The company reported strong growth and secured major new NASA contracts.
As the regular session of the US market on Wednesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Stay updated with the movements of the S&P500 index one hour before the close of the markets on Wednesday. Discover which stocks are leading as top gainers and losers in today's session.
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
Stay tuned for the market movements in the S&P500 index on Wednesday. Check out the gap up and gap down stocks in the S&P500 index during today's session.
Jerash Holdings (JRSH) reports mixed Q2 FY2026 results, with revenue beating estimates but EPS missing forecasts. The stock fell on the earnings miss despite a positive sales outlook for the next quarter.
Astria Therapeutics missed Q3 2025 earnings and revenue estimates, but the stock's focus remains on its promising HAE drug pipeline and the pending acquisition by BioCryst.
Genpact (G) is a quality investment with strong profitability, low debt, and consistent growth. Its solid financial health and reasonable valuation make it ideal for long-term investors.
Let's have a look at what is happening on the US markets before the opening bell on Wednesday. Below you can find the top gainers and losers in today's pre-market session.
Ovid Therapeutics announces CEO succession plan and key pipeline progress for epilepsy drug OV329 and KCC2 activators, backed by a strong cash position.
Humacyte (HUMA) missed Q3 revenue estimates but delivered a smaller-than-expected loss per share. The stock rose as investors focused on its pipeline progress toward key regulatory milestones.
Milestone Pharmaceuticals beat Q3 earnings estimates, with a narrower loss. The stock rose as investors await the December 2025 FDA decision for its lead drug, CARDAMYST™.
Abeona Therapeutics beat Q3 EPS estimates but missed on revenue. The stock fell as investors focus on the delayed launch of its new gene therapy, ZEVASKYN.
Agnico Eagle Mines (AEM) stock shows a powerful mix of strong technical uptrend and accelerating fundamental growth, making it a top pick for momentum investors.
Caesarstone (CSTE) Q3 2025 results show revenue beat estimates, but earnings missed with a wider loss. The company announced a major restructuring to cut costs.
United Therapeutics (UTHR) offers strong value with a low P/E ratio, zero debt, and high profitability. This biotech stock presents a compelling opportunity for value investors.
Discover how Shoals Technologies (SHLS) fits the Minervini Trend Template, combining a strong technical uptrend with accelerating earnings and sales growth for high-growth momentum investors.
On Holding AG (ONON) Q3 2025 earnings smash expectations with a 74% EPS beat and strong sales, leading to a raised 2025 outlook and a major stock surge.
